Century Therapeutics (IPSC) reported a Q3 2026 net loss of $23.5M, improved from $34.4M a year ago. Cash and investments stood at $174.1M, funding operations into 1Q 2029. The company reiterated plans to submit an IND for its type 1 diabetes therapy CNTY-813 in 4Q 2026 and to initiate a clinical trial for CNTY-308 in 2026.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
